# China NMPA Inspection - Beijing Rimeng Biotechnology Co., Ltd. - December 19, 2018

Source: https://www.globalkeysolutions.net/records/china_inspection/beijing-rimeng-biotechnology-co-ltd/4897fc22-005d-4af5-b6ce-f0d046f7a065/
Source feed: China

> China NMPA unannounced inspection for Beijing Rimeng Biotechnology Co., Ltd. published December 19, 2018. An unannounced inspection of Beijing Rimeng Biotechnology Co., Ltd., conducted by the Former State Food and Drug Administration Food and Drug Inspecti

---

## Details

- Record Type: CHINA_INSPECTION
- Title: Notification of unannounced inspection of Beijing Rimeng Biotechnology Co., Ltd.
- Company Name: Beijing Rimeng Biotechnology Co., Ltd.
- Publication Date: 2018-12-19
- Product Type: Cosmetics
- Summary: An unannounced inspection of Beijing Rimeng Biotechnology Co., Ltd., conducted by the Former State Food and Drug Administration Food and Drug Inspection and Testing Center and Beijing Municipal Food and Drug Administration, identified significant deficiencies. The inspection, based on the "Key Points for Cosmetic Production License Inspection," was reported on December 19, 2018. Inspectors found four serious and eight general defects. Critical issues included the absence of a separate production workshop and adequate facilities for the wax-based manufacturing unit, and a lack of dedicated production equipment for this unit and pulverizing equipment for the powder unit. Significant cross-contamination risks were noted due to unseparated personnel and material flow, and directly open packaging rooms in the powder unit. Additionally, product coding and batch numbering systems were inconsistent, hindering traceability. General violations encompassed incomplete quality management documentation, such as missing controlled labels on system documents, and a lack of established inspection standards for raw materials and finished products. Raw material and semi-finished product storage lacked proper labeling, location cards, and essential batch information. Insufficient retained samples and incomplete internal audit records were also identified. The company is required to rectify all identified issues within a specified period. The Beijing Municipal Drug Administration will oversee this corrective action, and Beijing Rimeng Biotechnology Co., Ltd. must report its progress to the Cosmetics Supervision Department of the State Drug Administration within two months.

Company: https://www.globalkeysolutions.net/companies/beijing-rimeng-biotechnology-co-ltd/cb7dbba6-a363-439d-825b-b49b9ca23ee7/